Table 1.
Clinical Data Among Disseminated TM Patients Treated With IVCY
| Patient No. | Age/Sex | Organ Involvement | Underlying Diseases | Treatment Duration Before IVCY, mo | No. of Relapses Before IVCY Treatment | Other Opportunistic Infections/Organ |
|---|---|---|---|---|---|---|
| 1 | 63/M | Blood, lymph nodes, lung, liver, spleen, skin, multiple bones | … | 19 | 3 | M. chelonae: lung |
| 2 | 62/M | Lung, liver, multiple bones, lymph nodes | Atrial fibrillation ANA1:100 | 13 | 1 | … |
| 3 | 43/F | Lung, skin, blood, multiple bones, lymph nodes | Bronchial asthma Sweet's syndrome ANA1:100 anticardiolipin antibody (+), anti-Ro-52 antibody (±) | 12 | 3 |
M. abscessus: lung, bones Salmonella: blood, alimentary canal |
| 4 | 33/F | Lung, skin lymph nodes, multiple bones, liver, spleen | ANA 1:320, anti-SSA antibody (+), anti-SSB antibody (+) | 6 | 1 | M. abscessus: lung |
| 5 | 64/M | Lung, skin, lymph nodes, multiple bones, blood | … | 14 | 2 | Salmonella: blood |
Abbreviations: ANA, antinuclear antibody; IVCY, intravenous cyclophosphamide; NTM, nontuberculous mycobacteria; TM, Talaromyces marneffei.